<DOC>
	<DOCNO>NCT02126020</DOCNO>
	<brief_summary>The Boston Keratoprosthesis type I ( KPro ) prosthetic cornea use treat several cause corneal blindness . Some category patient , include auto-immune disease Stevens-Johnson syndrome , toxic epidermal necrolysis syndrome mucous membrane pemphigoid , high risk failure KPro . Because chronic inflammation , cornea support KPro may melt , lead high risk infection , loss KPro loss eye . Infliximab antibody tumor necrosis factor alpha use intravenously control inflammation several disease . It use case corneal melt significant success . This study 's hypothesis infliximab successfully use eye drop ( instead usual administration vein ) regular use may prevent melt eye Boston Keratoprosthesis type I underlie auto-immune disease .</brief_summary>
	<brief_title>Topical Infliximab Autoimmune Eyes With Keratoprosthesis</brief_title>
	<detailed_description>This unmasked , prospective , multicenter clinical trial four patient candidate Boston Keratoprosthesis prior KPro surgery diagnosis Stevens-Johnson syndrome ( SJS ) , toxic epidermal necrolysis syndrome ( TENS ) mucous membrane pemphigoid ( MMP ) . Only one eye per patient consider inclusion . This phase I/II study evaluate safety tolerance topical infliximab 10 mg/mL eye drop . Research subject require administer infliximab eye drop four time per day three month follow twice daily administration nine month . The subject monitor study medication well one year follow discontinuation drug . The total study duration patient two year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<mesh_term>Pemphigoid , Benign Mucous Membrane</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Age 18 80 year Able provide inform consent Underlying diagnosis SJS , TENS , MMP Implantation Boston KPro type I Able administer eye medication care giver able willing Negative tuberculosis screen Active recurrent ocular systemic infection Chest radiography , QuantiFERONTB Gold purify protein derivative ( PPD ) evidence active latent tuberculosis infection Indeterminate initial repeat QuantiFERONTB Gold result History Bacille CalmetteGuerin ( BCG ) vaccination within twelve month screen History latent active granulomatous infection , include histoplasmosis coccidioidomycosis , prior screen Chest radiograph within three month prior first administration study drug show abnormality suggestive malignancy current active infection , include tuberculosis . History nontuberculous mycobacterial infection opportunistic infection ( e.g . cytomegalovirus , pneumocystosis , aspergillosis ) within six month prior screen history hepatitis B virus Methicillin resistant Staphylococcus aureus ( MRSA ) vancomycin resistant enterococcus ( VRE ) infection Malignancy diagnose last five year Demyelinating disease History current diagnosis diabetes mellitus ( control uncontrolled ) Heart failure ( New York Heart Association class III IV ) Pregnancy breastfeed Scheduled receive live vaccine time point study participation Allergy infliximab compound topical formulation chemicallyrelated medication Prior current use systemic antitumor necrosis alphaÎ± medication currently receive treatment Kineret ( Anakinra ) KPro design less 16 hole back plate ( avoid confounder corneal nutrition ) Inability comply instillation additional drop Unable attend postoperative visit administer medication , care giver available willing assist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Keratoprosthesis</keyword>
	<keyword>corneal melt</keyword>
	<keyword>keratolysis</keyword>
	<keyword>Tumor necrosis factor alpha</keyword>
	<keyword>infliximab</keyword>
	<keyword>matrix metalloproteinase</keyword>
</DOC>